Business News • PR NewsWire • New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th

New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th

New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th

STOCKHOLM, Aug. 30, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that new updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study will be presented at at the 17th International Myeloma Workshop (IMW) meeting on September 15, Boston,...

View More : https://www.prnewswire.com:443/news-releases/new-updated-data-will-be-presented-from-oncopeptides-pivotal-phase-2-horizo...

Releted News by prnewswire

Inbound Marketing Strategies Yield Positive Results and Increased Leads for Businesses, Survey Finds

Two-Day 'DNA Accredited' Business Advisor Training: Enhance Leadership and Performance

Essity and UNICEF in Mexico Strengthen Collaboration on Hygiene Issues

SKF Makes Group Management Appointment